Epidemic of mumps among vaccinated persons, the Netherlands, 2009-2012 by Sane, J. (Jussi) et al.
To analyze the epidemiology of a nationwide mumps 
epidemic in the Netherlands, we reviewed 1,557 notified 
mumps cases in persons who had disease onset during 
September 1, 2009–August 31, 2012. Seasonality peaked in 
spring and autumn. Most case-patients were males (59%), 
18–25 years of age (67.9%), and vaccinated twice with mea-
sles-mumps-rubella vaccine (67.7%). Nearly half (46.6%) 
of cases occurred in university students or in persons with 
student contacts. Receipt of 2 doses of vaccine reduced 
the risk for orchitis, the most frequently reported complica-
tion (vaccine effectiveness [VE] 74%, 95% CI 57%–85%); 
complications overall (VE 76%, 95% CI 61%–86%); and 
hospitalization (VE 82%, 95% CI 53%–93%). Over time, 
the age distribution of case-patients changed, and propor-
tionally more cases were reported from nonuniversity cities 
(p<0.001). Changes in age and geographic distribution over 
time may reflect increased immunity among students result-
ing from intense exposure to circulating mumps virus.
Mumps is an acute illness caused by mumps virus (family Paramyxoviridae) and characterized by fe-
ver, swelling, and tenderness of >1 salivary gland, usually 
the parotid gland. Complications associated with mumps 
include orchitis (inflammation of the testes), meningitis, 
pancreatitis, and deafness. Mumps virus is spread in re-
spiratory droplets, and the incubation period is 15–24 days 
(median 19) (1). 
Vaccination for mumps has been in use in industri-
alized countries for decades (2). The Netherlands began 
mumps vaccination in 1987, using the measles, mumps, 
and rubella combination vaccine (MMR). The vaccine, 
containing the Jeryl-Lynn mumps virus strain, is admin-
istered in a 2-dose schedule at 14 months and 9 years of 
age. Vaccination coverage of >1 dose of MMR has consis-
tently been >93% since the introduction of the vaccination 
program (3). After the MMR program was launched, the 
incidence of mumps in the Netherlands decreased consid-
erably; nevertheless, during the 2000s, several mumps out-
breaks were detected. In 2004, an outbreak occurred among 
students at an international school (4), and in 2007–2008, 
an outbreak was detected mainly in a religious community 
that had low vaccination coverage (5). Since the end of 
2009, a countrywide epidemic has been ongoing, affecting 
mainly student populations (6,7).
Mumps was notifiable in the Netherlands before 1999 
and was made notifiable again in December 2008 (5). Mumps 
surveillance reports are released biweekly or monthly and 
include data on age and sex distribution, geographic distri-
bution, vaccination, and contact status of case-patients. The 
report is distributed to public health professionals, including 
epidemiologists, virologists, and local-level health profes-
sionals, but comprehensive spatiotemporal characterization 
of the surveillance data has not been conducted. To pro-
vide information for future mumps prevention efforts, we 
used this surveillance data to assess the rates of illness and 
complications associated with the ongoing outbreak, to un-
derstand who is at risk for infection, and to assess whether 
transmission patterns have changed over time.
Methods
We reviewed data on mumps cases reported to the 
registration system for notifiable infectious diseases in the 
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Netherlands (OSIRIS) during September 1, 2009–August 
31, 2012. Notification criteria for mumps include >1 re-
lated symptom (i.e., acute onset of painful swelling of the 
parotid or other salivary glands, orchitis, or meningitis) 
and laboratory confirmation of infection or an epidemio-
logic link to a laboratory-confirmed case (7). In addition to 
basic demographic information, notification data reported 
to OSIRIS included vaccination status and student or con-
tact with student status. The questions on student/student 
contact status were made more specific on April 19, 2010. 
For cases reported before that date, the information for the 
new variable was obtained from open-format questions. 
Laboratory confirmation criteria included >1 of the follow-
ing: detection of mumps-specific IgM; detection of viral 
RNA; or isolation of the virus on cell culture. Genotyping 
targeting the gene encoding the small hydrophobic protein 
was performed on specimens submitted to the National In-
stitute for Public Health and the Environment by using an 
in-house method. 
We used the χ2 test for comparison of proportions and 
testing for trends over time and calculated a 3-week mov-
ing average to characterize trends and seasonality. Vac-
cine effectiveness (VE) was estimated as 1 – odds ratio. 
The odds ratio, which describes the association between 
complications/hospitalizations and vaccination status, was 
adjusted for age and sex (when outcome was orchitis, ad-
justment was done for age only) and estimated by using 
logistic regression. Associations with p values of <0.05 
were considered statistically significant, and all reported p 
values are 2-tailed. Stata software version 12 (StataCorp, 
College Station, TX, USA) was used for the analyses.
Results
During September 1, 2009–August 31, 2012, a total 
of 1,557 cases of mumps were reported in the Netherlands 
(Figure); 1,254 (80.5%) of these were laboratory confirmed. 
Laboratory confirmation was most often by detection of vi-
ral RNA (68.8%), followed by antibody detection (21.9%) 
and virus isolation (7.3%). In 2% of cases, 2 methods were 
combined for diagnosis. 
Most case-patients were male (59%) and 18–25 years 
of age (67.9%). The average annual incidence per 100,000 
population was 0.5 for the 0–3-year age group, 0.8 for the 
4–14-year age group, 4.5 for the 13–17-year age group, 
21.4 for the 18–25-year age group, and 0.9 for the >25-year 
age group. Of the 1,474 cases for which patient vaccina-
tion status was reported, 998 (67.7%) case-patients had re-
ceived 2 doses of MMR; 157 (10.6%) had received 1 dose, 
and 242 (16.4%) were unvaccinated. Genetic analysis of 
small hydrophobic gene sequences of 808 mumps-positive 
samples showed that most (98.5%) outbreak strains be-
longed to the G5 subtype.
Complications were reported in 126 cases (8.4% of 
1,492 cases with known complication status) (Table 1). 
Most (78 [62%]) complications occurred in the 18–25-year 
age group. Orchitis was the most frequent complication 
(109 [12.7%] male case-patients >12 years of age) and oc-
curred significantly more often among unvaccinated case-
patients than among case-patients who had received 1 vac-
cine dose (p = 0.04); vaccination with 2 doses of MMR 
reduced the risk for orchitis even further (p<0.01). Other 
reported complications were meningitis (n = 6), pancre-
atitis (n = 3), thyroiditis (n = 1), and encephalitis (n = 1). 
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Figure. Numbers of notified mumps 
cases, by week of onset, The 
Netherlands, September 1, 2009–
August 31, 2012 (N = 1,557 cases). 
Seasons and number of cases (n) 
are indicated; black line indicates 
3-week moving average.
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Three case-patients had permanent unilateral hearing loss 
that was probably caused by mumps virus infection. Deaf-
ness and meningitis occurred more frequently among un-
vaccinated than vaccinated persons, but those numbers 
were probably too low for statistical significance (Table 1). 
A total of 31 patients (2.1% of 1,436 patients with 
known hospitalization status) were hospitalized. Risk for 
hospitalization was significantly lower among case-patients 
who had received 2 MMR doses than for unvaccinated 
case-patients (p<0.01); VE for preventing hospitalization 
was 82% (Table 1). Of the 31 hospitalized case-patients, 13 
(42%) had orchitis. No deaths were reported.
Three distinct epidemic seasons occurred during the 
outbreak: seasonal peaks in spring and late autumn and a 
decline in number of cases during summer and, to some ex-
tent, during the Christmas holidays (Figure). Data on sex, 
age, vaccination status, residence in a city with a university, 
student status, and contact with student status by season are 
shown in Table 2. Overall, the age distribution of mumps 
case-patients differed significantly between the seasonal 
peaks (p = 0.007). The number of cases increased propor-
tionally over time for the 13–17-year age group (p = 0.003) 
and the >25-year age group (p = 0.042) and decreased over 
time for the 18–25-year age group (p<0.001). The overall 
proportion of cases in vaccinated persons did not change 
(Table 2), and the proportion of complications or hospital-
izations did not differ by season (data not shown).
We found significant seasonal differences in the pro-
portion of cases occurring in students and in persons with 
student contacts (p<0.001). During early spring 2010, 
large clusters of cases were reported from university cit-
ies of Leiden and Delft, as described (6). However, dur-
ing 2011 and 2012, proportionally more case-patients were 
not students and had no contact with students than during 
2010 (p<0.001). The proportion of student case-patients 
enrolled in higher education other than university or case-
patients who had contact with these nonuniversity students 
increased after 2010 (p<0.001). The absolute numbers of 
cases in these categories increased from 2010 to 2011 but 
stayed more or less constant, or decreased slightly, in 2012. 
The number of case patients who were university students 
or who had contact with university students decreased 
proportionally (p<0.001), and over time, proportionally 
more cases were reported from cities without universities 
(p<0.001). In addition, the total number of cases from non-
university cities was higher in 2012.
Discussion
The epidemic of mumps in the Netherlands during late 
2009 through 2012 affected mainly vaccinated students. 
However, vaccination evidently offered protection against 
mumps-associated complications. The epidemic showed a 
seasonal trend, although cases were identified throughout 
the years. Over time, age, student status, and geographic 
distribution changed, which suggests a slight shift in trans-
mission trends from student populations to younger and 
older nonstudent populations and to cities without a uni-
versity. This shift may relate to increased immunity in the 
primarily affected high-risk student population; exposure 
to wild-type mumps virus may have boosted individual im-
munity and thus contributed to increased herd immunity.
Mumps outbreaks among vaccinated populations have 
been reported in other countries during recent years: a 
2006 outbreak in the United States (8), a 2009–2010 out-
break in Canada (9), and a 2012 outbreak in the United 
Kingdom (10). Description of an outbreak in 2009–2010 
in the northeastern United States among a highly vacci-
nated population of Orthodox Jews indicated that intense 
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Table 1. Association between rates of mumps complications and hospitalization and MMR status, the Netherlands, September 1, 
2009–August 31, 2012* 
Complication 
No. MMR 
doses received 
by case-patient 
No. (%) case-
patients with 
complications Crude OR (95% CI) p value aOR† (95%CI) p value aVE† (95% CI) 
Orchitis§ 0 36 (15.5) Ref  Ref Ref Ref 
 1 10 (6.6) 0.46 (0.22–0.97) 0.04 0.46 (0.22–0.98) 0.04 54 (2–78) 
 2 46 (4.7) 0.26 (0.16–0.41) <0.01 0.26 (0.15–0.43) <0.01 74 (57–85) 
Deafness 0 2 (0.9) Ref     
 1 0 NA NA – – – 
 2 1 (0.1) 0.12 (0.01–1.3) 0.1 – – – 
Meningitis 0 2 (0.8) Ref     
 1 1 (0.6) 0.76 (0.07–8.5) 0.8 – – – 
 2 2 (0.2) 0.24 (0.03–1.7) 0.2 – – – 
All complications 0 44 (19.0) Ref  Ref Ref Ref 
 1 10 (6.6) 0.30 (0.15–0.62) <0.01 0.29 (0.14–0.62) <0.01 71 (38–86) 
 2 55 (5.7) 0.26 (0.17–0.39) <0.01 0.24 (0.14–0.39) <0.01 76 (61–86) 
Hospitalization 0 11 (4.8) Ref  Ref Ref Ref 
 1 3 (2.0) 0.41 (0.11–1.5) 0.18 0.43 (0.11–1.6) 0.2 57 (–60 to 89) 
 2 10 (1.1) 0.22 (0.09–0.52) <0.01 0.18 (0.07–0.47) <0.01 82 (53–93) 
*Only case-patients with known complications and vaccination status were included in the analyses. OR, odds ratio; VE, vaccine effectiveness; Ref, 
referent; NA, not applicable; –, not analyzed (insufficient sample size). 
†Adjusted for age (age groups <18 y, 18–25 y, >25 y) and sex, except orchitis, which was adjusted only for age. 
§Includes only male case-patients >12 y of age. 
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exposure among boys in a religious school facilitated the 
transmission of mumps virus, which overpowered the vac-
cine-induced protection (11,12). Similar to our findings, 
transmission in that outbreak shifted from adolescents to 
younger and older populations over time. The intense social 
crowding among students (e.g., large indoor social gath-
erings) partly explains why secondary vaccine failure oc-
curred in the outbreak described in this study. A subgroup 
of students, including those living with many other students 
and members of university fraternities, may be at increased 
risk for infection (6,7). Crowding in nonstudent popula-
tions may not be as intense as among students, and mixing 
is usually with more heterogeneous age groups. In these 
circumstances, herd immunity is sufficient to prevent more 
widespread transmission. A lower rate of crowding may 
be one explanation for the relatively low numbers of cases 
among 4–12-year-olds, despite the generally lower IgG 
titers in this group than in adolescent students (13). Still, 
even though lower antibody levels do not automatically 
mean higher risk for mumps virus infection (14), a higher 
rate of illness would have been expected in the 4–12-year 
age group. An additional explanation for the lower apparent 
illness rate among these younger children might be a higher 
frequency of unapparent and subclinical infections, which 
would lead to many undiagnosed cases in this age group.
Most of the persons affected in the epidemic were 
male, a finding also observed in other studies (15,16). The 
reasons for male predominance are unclear, but significant-
ly higher mumps antibody titers in female than in male per-
sons have been demonstrated (13,17); this finding, in turn, 
may be linked to gender-associated genetic differences in 
immune response. Behavioral differences between sexes 
may also play a role.
Most cases occurred in persons who had received 2 
doses of MMR, which suggests inadequate effectiveness 
of the vaccine. Recent studies indicate the effectiveness 
of MMR against mumps is moderate and lower than the 
clinical efficacy estimates (1,18). Postlicensure studies of 
2 doses (Jeryl-Lynn strain) of MMR have provided a me-
dian VE estimate of 88% (range 79%–95%) (2). A recent 
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Table 2. Demographic characteristics and student status for 1,557 patients with mumps, by annual epidemic season, the Netherlands, 
September 1, 2009–August 31, 2012* 
Characteristic 
No. (%) case-patients 
Season 1, 2009 Sep 1–
2010 Aug 31, n = 359 
Season 2, 2010 Sep 1–
2011 Aug 31, n = 689 
Season 3, 2011 Sep 1–
2012 Aug 31, n = 509 
Sex    
 M 205 (57.1) 416 (60.4) 296 (58.2) 
 F 154 (42.9) 271 (39.3) 213 (41.8) 
 Unknown 0 2 (0.3) 0 
Age, y    
 0–3 3 (0.8) 4 (0.6) 3 (0.6) 
 4–12 5 (1.4) 22 (3.2) 16 (3.1) 
 13–17 17 (4.7) 63 (9.1) 54 (10.6) 
 18–25 270 (75.2) 468 (67.9) 318 (62.4) 
 >25 64 (17.8) 131 (19) 118 (23.2) 
 Unknown 0 1 (0.2) 0 
Vaccination status    
 0 doses 57 (15.9) 115 (16.7) 70 (13.7) 
 1 dose 37 (10.3) 69 (10.0) 51 (10.0) 
 2 doses 225 (62.7) 436 (63.3) 337 (66.2) 
 >3 doses 4 (1.1) 4 (0.6) 5 (1.0) 
 Vaccinated but unknown no. doses 24 (6.7) 25 (3.6) 15 (3.0) 
 Unknown 12 (3.3) 40 (5.8) 31 (6.1) 
Residence in a city with university†    
 Yes 258 (71.9) 351 (50.9) 243 (47.7) 
 No 92 (25.6) 322 (46.7) 263 (51.7) 
 Unknown 9 (2.5) 16 (2.3) 3 (0.6) 
Student/contact with students    
 Not a student and no contact with students 22 (6.1) 171 (24.8) 118 (23.2) 
 University student or contact with university  
 students 
229 (63.8) 275 (39.9) 221 (43.4) 
 Other student‡ or contact with other students 20 (5.6) 144 (20.9) 88 (17.3) 
 Unknown 88 (24.5) 99 (14.4) 82 (16.1) 
Incidence estimates§    
 University students 92.9 93.9 80.2 
 Other students 2.0 14.7 9.8 
 Secondary school students 0 0.7 5.4 
*Boldface indicates significance trends by 2 test, calculated by using proportions excluding unknowns. 
†University cities: Amsterdam, Delft, Eindhoven, Enschede, Groningen, Leiden, Maastricht, Nijmegen, Rotterdam, Stichtse Vecht, Tilburg, Utrecht, and 
Wageningen. 
‡Students enrolled in higher education other than university. 
§Incidence per 100,000 students. Total student numbers by category obtained from www.cbs.nl. 
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study of an outbreak of mumps at a student party in the 
Netherlands estimated a VE of 68% for 2 doses of MMR 
(6). This estimate is, however, uncertain because of the low 
number of unvaccinated case-patients. We attempted to 
provide VE estimates against clinical mumps applying the 
screening method; however, because this method is most 
vulnerable to error when proportions of the population and 
case-patients vaccinated are high (19), as in this study, the 
estimates became inaccurate and thus are not included in 
our results. The possible causes for lower than expected 
VE include secondary vaccine failure (waning immunity), 
intense exposure to high virus inoculum, and a possible 
mismatch between the vaccine genotype and circulating 
strains (1,2,18,20). However, because the level of antibod-
ies correlating with protection remains unknown (12,21), 
we are unable to further elucidate the role of these factors.
Orchitis was the most common complication, consistent 
with previous outbreaks in a population with a similar age 
structure (1). However, orchitis occurred significantly more 
often among unvaccinated than vaccinated case-patients, 
and the vaccine was effective in preventing orchitis, which 
has previously been shown in a study based in part on the 
same study population (22) and in other studies (11,23). 
Vaccination also significantly reduced the risk for complica-
tions overall and for hospitalizations. A previous report de-
scribed 3 cases of deafness (0.19% of all notified infections), 
2 in unvaccinated persons (24). The frequency of 0.005% 
for unilateral deafness commonly cited in the literature (25) 
is considerably lower than that found in our study, but this 
difference is likely attributable to a different denominator 
population. A higher incidence of deafness has been reported 
from Japan using more appropriate denominators (26). 
One limitation of our study was the short time span for 
assessing changes over time. Mumps cases have continued 
to occur after our study period, but the number of cases 
reported after September 2012 (180 as of August 31, 2013) 
is much lower than that reported during the previous years. 
Recent numbers indicate that a similar trend in changing 
patterns of age and geographic distribution is ongoing; 
most of the more recent cases have occurred in nonstudents 
and in age groups other than 18–25 years (data not shown). 
However, because of lower case numbers, this comparison 
must be interpreted with caution. 
A further limitation of our study is that it is likely that 
many mumps cases are not notified because they are subclini-
cal infections or because of reluctance to seek medical care; 
thus, these cases are not included in our analyses. Furthermore, 
complications that occurred after the notification date are not 
included; however, because vaccination status is probably not 
associated with the reporting of complications, we regard our 
VE estimates against complications as unbiased.
Although VE for mumps vaccination is not optimal 
for preventing clinical disease, our results support previous 
findings that vaccination limits the severity of disease. Be-
cause complications are the primary mumps-associated 
public health problem, these findings support the current 
vaccination recommendations. Still, this epidemic demon-
strates that mumps virus can cause large outbreaks even in 
highly vaccinated populations. The observation that the in-
cidence after the third season studied has been considerably 
lower than during previous seasons is consistent with the 
development of herd immunity among high-risk students 
resulting from the high rate of natural symptomatic and as-
ymptomatic infections. However, the annual inflow of new 
susceptible students–unvaccinated and vaccinated–who 
start their studies could again lower overall immunity. A 
recent study suggested that use of a third MMR dose might 
be an effective control measure in certain outbreak situa-
tions (27). Introduction of a third MMR dose to the vacci-
nation schedule has been considered in the Netherlands (6) 
but was not recommended because of relatively low over-
all illness rates associated with mumps and other factors, 
including an expected low vaccine uptake. Although the 
vaccine remains effective in most settings and significantly 
reduces the risk for complications, further research is need-
ed to understand the limitations of MMR, and modeling 
is warranted to understand the dynamics of mumps virus 
transmission in future.
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